Munich-based Tubulis closed a large financing to push its next‑generation antibody‑drug conjugates (ADCs) through clinical development. Reports show the company raised roughly $360–361 million in a Series C to expand testing of lead candidate TUB‑040 into additional tumor types and earlier lines of therapy. Tubulis said the funds will also accelerate work across its ADC platform ahead of planned clinical presentations at major oncology meetings. Investors reported the round will support expanded trials in ovarian and non‑small cell lung cancer; company briefings emphasized plans to present first‑in‑human data and to scale manufacturing for broader clinical programs. The financing underscores continued investor appetite for novel ADC chemistry capable of improving therapeutic index versus conventional chemotherapy. Tubulis executives framed the cash as enabling both indication expansion for TUB‑040 and pipeline acceleration across conjugate assets.